Arcadia Bindery empowers data analysts to create compelling, personalized reports using beautiful and insightful visualizations to highlight performance and opportunities for improvement.
Arcadia customers will share best practices for success with interoperability, value-based care, predictive analytics, and more at HIMSS22. Visit us in Booth #2711, hear our customers speak in General Education Sessions, request an invite to one of our exclusive forums, join us for Sips & Socks or a party at Universal, and more!
Simplify the distribution and creation of personalized and contract-specific health plan reporting and focus analysts on high-value tasks with Arcadia Bindery
Arcadia was awarded the 2022 Best in KLAS designation for Value-Based Care Managed Services with a score of 88.2, marking the fourth consecutive year that Arcadia has earned the award.
The key finding of the analysis is that COVID patients had a high mortality rate post-discharge compared to the general population — and a mortality rate even higher than discharged patients who had a diagnosis of sepsis.
We hope to see you at the HIMSS22 Global Conference. Stop by Booth #2711 to meet our team and get a demo of Arcadia Analytics.
Insights from massive real world data assets can uncover complex interactions and drive hypothesis creation. Learn more about Arcadia's research on the impact of COVID-19 vaccinations in reducing long-COVID likelihood and severity.
Arcadia Vice President of Enterprise Partnerships, Anna Basevich, recently spoke with IMSNY CIO, Elise Kohl-Grant, about the lack of technology investment in behavioral health, how standardized data could open doors for new patient benefits, and why technology can lead to significant positive outcomes for the whole person care.
Arcadia Chief Product Officer, Nick Stepro and Castell Medical Director and Interim COO, Dr. Will Daines, discuss realigning payers and medical providers around mutual benefits value-based care, the technology needed to deploy that change, and the outcomes that it delivers to patients, providers, and payers.
Arcadia's new study, published on medRxiv, shows that current vaccines reduce the risk of long-COVID, even when administered up to 12 weeks after a COVID diagnosis.